Drug intelligence / Profile preview

zap-70 siRNA

Development stage
Preclinical
Lead developer
University of Cambridge
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

ZAP-70 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Zeta-chain-associated protein kinase 70 (ZAP-70), a tyrosine kinase that is aberrantly expressed in aggressive forms of Chronic Lymphocytic Leukemia (CLL). In IGHV-unmutated CLL, ZAP-70 acts as a critical scaffold and signaling molecule that integrates tonic B cell receptor (BCR) signaling and chemokine-mediated pathways, such as those involving CCL19 and CCL21. By degrading ZAP-70 mRNA through the RNA interference (RNAi) pathway, this siRNA inhibits the constitutive activation of downstream kinases like AKT and GSK-3beta and impairs leukemia cell migration. While currently utilized primarily as a research tool in primary cell cultures and co-culture systems, it represents a targeted approach to disrupting the signaling networks that drive CLL progression.

Other names
ZAP-70-specific siRNAZAP70-specific siRNAZAP 70-specific siRNAsiRNA targeting ZAP-70
02

Targets

ZAP70 (Zeta-chain-associated protein kinase 70)

Beyond the preview

Go deeper on zap-70 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on zap-70 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call